Cited by 34Epigenetics and DNA MethylationColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Association of TET1 expression with colorectal cancer progression

Tian, Yiping, Pan, Feixia, Sun, Xiaohui, Gan, Meifu, Lin, Aifen, Zhang, Dandan, Zhu, Yimin, Lai, Maode·2017·Scandinavian Journal of Gastroenterology

Abstract

OBJECTIVE: The ten-eleven translocation (TET) proteins, as methylcytosine dioxygenases, catalyze 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC). The altered expression of TET1 disrupts the balance between DNA methylation and demethylation. This alteration has been reported to be associated with carcinogenesis in various malignancies. The aim of the present study was to investigate changes in expression and the role of TET1 in colorectal cancer (CRC). MATERIAL AND METHODS: A total of 109 CRC patients who underwent radical surgical colon resection were enrolled. The QuantiGene Plex Assay was used to detect the expression of TET1 in CRC tissues and matching adjacent normal tissues. We analyzed the associations between TET1 expression levels and various clinicopathologic features of CRC. TET1 overexpression and depletion cells were constructed to investigate its biological role in CRC. RESULTS: Compared to normal tissues, the expression level of TET1 in CRC was significantly lower. The ratio of TET1 in CRC tissues to that in adjacent normal tissues (C/N-TET1) was an independent overall survival predictive factor. Moreover, in vitro studies showed that TET1 could inhibit cell growth and promote cell metastasis and invasion. CONCLUSIONS: These findings indicated that TET1 played a multifaceted role in the pathogenesis of CRC, and thereby resulting in multiple effects on tumor progression.

Integrity signals

Registry

Crossref · 10.1080/00365521.2016.1253767

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many colorectal cancers have low TET expression and relatively high HIF1α expression.

    “In fact, reports show that many CRCs have low expression levels of TETs and relatively high expression levels of HIF1α, implying that pharmacological ascorbate may attack multiple nodes in tumours with minimum toxicity102,103, making it an ideal magic bullet’ for cancer therapy.”

    From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [103]

  • Ascorbate treatment might hit several targets in tumours while causing little toxicity.

    “In fact, reports show that many CRCs have low expression levels of TETs and relatively high expression levels of HIF1α, implying that pharmacological ascorbate may attack multiple nodes in tumours with minimum toxicity102,103, making it an ideal magic bullet’ for cancer therapy.”

    From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [103]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Tian, Y., Pan, F., Sun, X., Gan, M., Lin, A., Zhang, D., Zhu, Y., & Lai, M.
Affiliations
  • Zhejiang Cancer Hospital (CN)
  • Zhejiang University (CN)
  • Zhejiang Taizhou Hospital (CN)
  • Wenzhou Medical University (CN)
Corresponding author
  • Zhu, Yimin
  • Lai, Maode
Venue
Scandinavian Journal of Gastroenterology
Published
2016-11-16
Volume
52
Issue
3
Pages
312-320
ISSN
  • 0036-5521 (ISSN-L)
  • 1502-7708
OpenAlex
W2550788914
Cited by
34
References
35
Citations by year
2025: 3 · 2024: 2 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 6 · 2019: 8 · 2018: 2 · 2017: 3
FWCI
2.25
Type
journal article
Language
en
Open access
closed
Locations
  • Scandinavian Journal of Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Key Science & Technology special project of Zhejiang Province (2012C13014-3)
  • 111 Project (B13026)
  • National Natural Science Foundation of China (81090420/81090421)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
TET1, colorectal cancer, DNA demethylation, 5-hydroxymethylcytosine, 5-methylcytosine, tumor progression, overall survival, prognostic factors, cell invasion, metastasis, cell growth inhibition
MeSH terms
Adult, Aged, Aged, 80 and over, Cell Movement, China, Humans, Mixed Function Oxygenases, Male, Middle Aged, Proto-Oncogene Proteins, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Proportional Hazards Models, Disease Progression, DNA Methylation, Cell Proliferation, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review